Antisense p53 oligonucleotides inhibit proliferation and induce chemosensitivity in follicular thyroid cancer cells

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1171-1176

  Hassan, Iyad ^a   Wunderlich, A ^a   Burchert, A ^a   Hoffmann, S ^a   Zielke, A ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Angiogenesis; FTC133 thyroid cancer cell line; ODN; Oligodesoxyribonucleotide phosphothioates; p53; Undifferentiated thyroid cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTARABINE; MUTANT PROTEIN; PROTEIN P53; RNA DIRECTED DNA POLYMERASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; NECROSIS; PRIORITY JOURNAL; THYROID CANCER;

ADENOCARCINOMA, FOLLICULAR; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTARABINE; GENES, P53; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; POINT MUTATION; THYROID NEOPLASMS; TRANSFECTION;

EID: 33645816808     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE and Fojo T: Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 83: 2516-2522, 1998.
2. Nagayama Y, Shigematsu K, Namba H, Zeki K, Yamashita S and Niwa M: Inhibition of angiogenesis and tumorigenesis and induction of dormancy by p53-null thyroid carcinoma cell line in vivo. Anticancer Res 20(4): 2723-2728, 2000.
3. Stein CA and Cheng YC: Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science 261: 1004-1012, 1993.
4. Bayever E, Haines KM, Iversen PL, Ruddon RW, Pirrucello SJ, Mountjoy CP, Arneson MA and Smith LJ: Selective cytotoxicitiy to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complemetary to p53 nucleotide sequence. Leuk Lymphoma 12: 223-231, 1993.
5. Fiedler A, Knorre Ch, Franke Y, Henne-Bruns D, Kremer B, Lüttges J, Maier M, Gerster M, Bleicher K, Bayer E and Kalthoff H: Growth inhibition of pancreatic tumor cells by modified antisense oligodeoxynucleotides. Langenbeck's Arch Surg 383: 269-275, 1998.
6. Jossart GH, Epstein HD, Shaver JK, Weier HU, Greulich KM, Tezelman S, Grossman RF, Siperstein AE, Duh QY and Clark OH: Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. J Clin Endocrinol Metab 81(10): 3498-3504, 1996.
7. Zielke A, Wong MG, Siperstein AE, Clark OH, Rothmund M and Duh QY: Antiproliferative effects of Suramin on primary cultures of human pheochromocytomas and rat PC12 pheochromocytoma cells. J Surg Oncol 66: 11-18, 1997.
8. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Golgfinger N, Pei H, Prokocimer M and Rotter V: Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 16(25): 3269-3277, 1998.
9. Narimatsu M, Nagayama Y, Akino K, Yasuda M, Yamamoto T, Yang TT, Ohtsuru A, Namba H, Yamashita S, Ayabe H and Niwa M: Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 83(10): 3668-3672, 1998.
10. Lowe SW: Cancer therapy and p53. Curr Opin Oncol 7(6): 547-553, 1995.
11. Müller H and Eppenberger U: The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 16(6B): 3845-3848, 1996.
12. Wynford-Thomas D: Origin and progression of thyroid epithelial tumors: cellular and molecular mechanisms. Horm Res 47: 145-157, 1999.
13. LaPerle KM, Jhiang SM and Capen CC: Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157: 671-677, 2000.
14. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grants CS, Thompson GB, van Heerden JA and Goellner JR: Anaplastic thyroid carcinoma: a 50 year experience at a single institution. Surgery 130: 1028-1034, 2001.
15. Lessin LS and Min M: Chemotherapy of anaplastic thyroid cancer. In: Thyroid Cancer: A Comprehensive Guide to Clinical Management, Wartowsky (ed.), Ottowa; Humana Press, pp. 337-340, 2000.
16. Blandino G, Levine AJ and Oren M: Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18(2): 477-485, 1998.